Biomarkers immune monitoring technology primer: Immunoscore® Colon by unknown
SHORT REPORT Open Access
Biomarkers immune monitoring technology
primer: Immunoscore® Colon
Fabienne Hermitte
Abbreviations: CC, Colon cancer; CRC, Colorectal cancer; CT, Core of the tumor; DAB, Diaminobenzidine;
DFS, Disease-free-survival; DP, Digital pathology; DSS, Disease-specific-survival; FFPE, Formalin-fixed paraffin-embedded;
IHC, Immunohistochemistry; IM, Invasive margin; INSERM, Institut national de la santé et de la recherche médicale;
IS, Immunoscore; IVD, In vitro diagnostic; MSI, Microsatellite instable; MSS, Microsatellite stable; OS, Overall survival;
QC, Quality control; ROI, Region of interest; RUO, Research use only; SITC, Society for immunotherapy of cancer;
TNM, Tumor burden/ lymph nodes/ metastases
Description of the technology
The Immunoscore® assay for Colon Cancer (IS Colon) is
the first standardized immune-based assay for the classi-
fication of cancer. It assesses the host immune response
to Colon Cancer (CC) by measuring intra- and peri-
tumoral T cell infiltration in formalin-fixed paraffin-
embedded (FFPE) tissue sections.
For each tumor sample, 2 slides are stained using an au-
tomated immunohistochemistry (IHC) staining instru-
ment (BenchMark XT, Ventana): one with CD3 and one
with CD8 ready-to-use monoclonal antibodies (HalioDx).
Detection is performed with the ultraView Universal DAB
Detection Kit (Ventana), followed by counterstaining in
order to visualize nuclei (Bluing Reagent, Ventana).
Stained slides are then washed, dehydrated, mounted
and coverslipped. Digital images of stained slides are
obtained using a whole slide scanner (Nanozoomer XR,
Hamamatsu), and analyzed by a software program (Immu-
noscore® Analyzer, HalioDx) if staining and image quality
is validated by the operator.
One separate control slide with 3 external controls −1
negative tissue (placenta) and 2 positive (1 tissue: tonsil
and a cell line pellet) - is processed identically in each
IHC run, and allows monitoring of the staining and
scanning steps.
Image processing
Digital images are imported into the Immunoscore®
Analyzer software and automatically processed for tissue
detection (core of the tumor (CT), healthy non-epithelial
tissue, and epithelium) and CD3 and CD8 positive lym-
phocytes quantification. The histotechnician reviews the
region annotations and modifies them if required; the in-
vasive margin (IM) is subsequently displayed automatic-
ally. Its width spans 360 μm into the healthy tissue and
360 μm into the tumor from the frontier between these
two tissue types.
Density and score calculation
After image processing validation by an independent re-
viewer, densities of CD3 and CD8 positive lymphocytes
in the 2 regions of interest (ROIs) CT or IM regions are
reported.
The best performing algorithm to compute the
Immunoscore has been defined in the large inter-
national SITC -led retrospective validation study [1, 2]
conducted on more than 3800 St I-III colon cancer pa-
tients, Briefly, for each marker (CD3 & CD8) and each
zone (CT & IM), densities distributions have been
established on the study training set; for each param-
eter of a tested sample (CD3, CD8, CT, IM), a percent-
ile is derived from these distributions. An average
percentile is calculated based on these 4 values. The
Immunoscore® is reported as IS-0, 1 – 2 – 3 – 4 based
on the following average percentile classes respectively:
[0 %; 10 %] - [>10 %; 25 %] - [>25 %; 70 %] - [>70 %;
95 %] - [>95 %; 100 %].
Reported prognostic information
Statistically significant prognostic groups have been de-
fined in the SITC study [2], with the Immunoscore®
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categories 0 and 1 indicating a bad prognosis (high risk
of relapse), while the Immunoscore® categories 3 and 4
indicate a good prognosis (low risk of relapse), and pa-
tients with an Immunoscore® 2 have an intermediate risk
of relapse.
Type of data obtained/readout
The Immunoscore® Analyzer generates a printable re-
port. This report contains a capture of all quality control
results as well as the analysis result.
Limitations of the approach
In order to get an accurate assessment of intra- and
peri-tumoral T-cell infiltration, the tumor specimen
must be selected from the block the most infiltrated by
immune cells and must contain both the core of the
tumor and the invasive margin. Pathologist review is
mandatory to qualify the selection of the specimen ac-
cording to those criteria prior to the testing.
The image analysis is a critical step in the process, and
digital pathology expertise is required. The Immunoscore®
assay is offered through HalioDx service laboratory and
will be initially implemented in expert centers only.
Finally Immunoscore® optimal performance were vali-
dated on a specific platform combining validated instru-
ments (autostainer and scanner) and qualified reagents.
Future equivalency studies will be conducted to qualify
additional platforms.
Types of samples needed and special issues
pertaining to samples
Starting material is a FFPE tissue block from a surgical
section of colon cancer. The block must contain the core
of the tumor (CT) and the invasive margin (IM) (tumor
and healthy tissue present in the sample). Samples must
have been fixed with 10 % buffered formalin. Slides must
be prepared less than 4 months before testing; 2 slides
are required (one for CD3, one for CD8) from adjacent
4 μm slices. Slices should be mounted on positively
charged glass slides (Superfrost™ Plus or equivalent).
Level of evidence
The role of adaptive immune response in controlling
tumor progression in colorectal cancer was first evi-
denced by Galon et al. in 2006 [3]. In a comprehensive
analysis of the tumor microenvironment, they showed
that the type, density and location of immune cells
within tumor regions predicted clinical outcome of the
patients. In particular, the combined analysis of immune
cells density in both tumor regions (CT and IM) was
shown to improve the accuracy of survival prediction as
compared to single-region analysis. It is based on those
observations that the Immunoscore® was established and
its prognostic power has been shown to surpass that of
the conventional TNM staging and clinicopathological
factors [3–6]. Notably, when Immunoscore® was applied
on two large independent cohorts of early-stage colorec-
tal cancer (n = 602), only 4.8 % of patients with a high
Immunoscore relapsed after 5 years as opposed to 72 %
of patients with a low IS indicating that these patients
could potentially have benefited from adjuvant therapy.
Recent data in large cohorts of CRC patients further
demonstrated the critical importance of IS over tumor-
related features in the mechanism of dissemination to
distant metastasis [7].
Immunoscore® was shown to be a stronger predictor of
survival than microsatellite instability status [8]. Microsat-
ellite instable (MSI) tumors often contain intra-epithelial
T cells in response to the expression of neo-antigens on
the cell surface and this probably contributes to the better
prognosis of patients with MSI tumors. Although patients
with IS-High tumors are overrepresented in the MSI
group compared to the microsatellite stable (MSS) group,
there is a substantial number of IS-High cases in the
MSS group, indicating that there is a good number of
MSS cases that are immunogenic. Patients with IS-
High tumors had statistically significant prolonged sur-
vival than patients with IS-Low tumors despite their
microsatellite status.
The last major Immunoscore® study conducted by the
Immunoscore® worldwide consortium, and led by the So-
ciety for Immunotherapy of Cancer (SITC) involved 23
pathology centers from 17 countries. This international
study including more than 3800 stage I/II/III colon cancer
patients aimed at promoting the Immunoscore® in routine
clinical setting [1,2]. Although CD45RO was one of the
markers used for Immunoscore assessment in previous
studies, because of background staining and loss of antige-
nicity in stored sections, it was agreed to employ the com-
bination of the two easiest membrane stains, CD3 and
CD8 in two regions (CT and IM) for validation in stand-
ard clinical practice [9]. The primary endpoint of the study
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was reached, with significantly longer TTR for patients
classified as IS-High in the training set (HR = 0.41
(CI95 %, [0.28–0.61]; p < 0.0001) and two independent
validation sets. Importantly, Immunoscore® discriminated
a subgroup of high-risk stage II patients. Immunoscore®
was also able to predict DFS and OS. Those major results,
beyond further validating Immunoscore® as a strong prog-
nostic marker also demonstrated that the assay was
quantitative, reproducible and robust through this multi-
centric study.
Altogether, those results might lead the introduction
of Immunoscore® into the cancer classification desig-
nated “TNM-I” (for TNM-Immune) and thereby help
with therapeutic decision in clinical routine [9].
Immunoscore® Colon is available through HalioDx ser-
vice laboratory, for research use only (RUO). By the end
of the year, pathologists will have access to an in vitro
diagnostic (IVD) assay in Europe, while a RUO solution
will also be available in the rest of the World.
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